Kevin S. Kapner - Concepedia

Author

Kevin S. Kapner

Dana-Farber Cancer Institute ORCID

Also Known As

Kevin Kapner, Kevin S Kapner, Kevin S. Kapner

317

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Broad Institute Brigham and Women's Hospital Massachusetts General Hospital

About

Kevin S. Kapner is an author at Dana-Farber Cancer Institute specializing in medicine, cell biology, and functional genomics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	260
2	Cell Biology	2	2	260
3	Pathology	1	1	182
4	Cancer Metabolism	1	1	78
5	Cell Signaling	1	1	182

Kevin S. Kapner

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer Srivatsan Raghavan, Peter Winter, Andrew W. Navia, Cell	2021	537
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer Julien Dilly, Megan T. Hoffman, Laleh Abbassi, Cancer Discovery Kras InhibitorsPancreatic CancerOncogenic AgentMedicineReceptor Tyrosine Kinase	2024	182
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer Xinyuan Tong, Ayushi S. Patel, Eejung Kim, Cancer Cell	2024	92
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity Hannah L. Williams, Andressa Dias Costa, Jinming Zhang, Cancer Research	2022	81
Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer Douglas E. Biancur, Kevin S. Kapner, Keisuke Yamamoto, Cell Metabolism Pancreatic CancerMedicineCancer GenomicsOmicsCell Biology	2020	78
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer Harshabad Singh, Rachel B. Keller, Kevin S. Kapner, Clinical Cancer Research	2023	42
Sotorasib Is a Pan- <i>RAS</i> G12C Inhibitor Capable of Driving Clinical Response in <i>NRAS</i> G12C Cancers Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Cancer Discovery	2024	38
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors James M. Cleary, Victoria Wang, Rebecca S. Heist, Clinical Cancer Research	2021	35
Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition Zackery A. Ely, Zachary Kulstad, Gürcan Günaydın, Science	2025	32
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition Andrew M. Waters, Tala O. Khatib, Bjoern Papke, Cell Reports	2021	31

Page 1